AstraZeneca

Adenovirus Vaccines Shown to Have Hematological Side Effect Concerns

As of yesterday, 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered throughout the United States. As of today, the CDC and FDA announced that they are reviewing six reported cases of a rare severe type of blood clot in individuals after receiving the vaccine” and are recommending a pause in the use of the single-dose Johnson & Johnson COVID-19 vaccine until a more thorough investigation can be conducted. The CDC will convene a meeting of the Advisory Committee on immunization practices (ACIP) tomorrow, Wednesday, April 14th, to further review these cases and assess their potential significance, and this analysis will also be reviewed by the FDA.

Read More »

Changing Vaccine Manufacturers Between Doses

The UK has established a vaccine protocol allowing patients to receive their first and second vaccine doses from different manufacturers. This is permissible if a second dose of the vaccine is unavailable or the manufacturer of the first dose is unknown. Currently, the only vaccines authorized for emergency use in the UK are by Pfizer, Moderna, and AstraZeneca.

Read More »

Astrazeneca’s COVID-19 Vaccine Demonstrates 76% Efficacy

AstraZeneca has released an updated statement revealing their vaccine demonstrates 76% efficacy against symptomatic COVID-19 and 100% efficacy against severe COVID-19 and hospitalization. They previously stated a 79% efficacy based on data through February 17, 2021. Experts credit this discrepancy to a rounding error.

Read More »

NIH Releases Statement Regarding AstraZeneca Vaccine

The National Institute of Allergy and Infectious Diseases (NIAID) published a news release today regarding AstraZeneca’s COVID-19 vaccine clinical trial, after being notified by the Data and Safety Monitoring Board that outdated information “may have provided an incomplete view of the efficacy data” (1). Which information is outdated has not been specifically disclosed. This statement was released one day after the NIH published a media advisory that the investigational AstraZeneca vaccine prevents COVID-19. 

Read More »